Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Clinical outcomes after cataract surgery with implantation of the multifocal Tecnis Symfony lenses

Search Title by author or title

Session Details

Session Title: Pseudophakic IOLs: Enlarged-Depth-of-Focus II

Session Date/Time: Monday 12/09/2016 | 16:00-18:00

Paper Time: 16:48

Venue: Hall C3

First Author: : K.Podboraczynska-Jodko POLAND

Co Author(s): :    W. Lubinski   M. Kirkiewicz                 

Abstract Details

Purpose:

To evaluate the clinical performance, efficicacy and safety of the multifocal Tecnis Symfony IOLs

Setting:

Clicical of Ophthalmology, Pomeranian Medical University, Szczecin, Poland

Methods:

Prospective study comprising 40 eyes of 20 patients undergoing cataract surgery with implantation of Symfony lenses. Three months postoperatively were evaluated: binocular uncorrected distance, intermediate and near visual acuities (UDVA, UIVA, UNVA)(logMAR), uncorrected binocular photopic and mesopic distance and photopic near contrast sensitivities (CSV-1000), spectacle independence, subjective symptoms, patient satisfaction (VFQ-25) and complications.

Results:

Three months after binocular uneventful surgery UDVA was equal of 0.1 or better. All eyes had binocular vision at 40 cm higher than 0.2. The intermediate vision was better than 0.35. Contrast sensitivities under different conditions were within normal age-matched limits. All patients were spectacle independent. Low level of halo perception was reported, less than 2 (0-4). Mean overall patient satisfaction was very high, more than 9.0 (0-10). No intra and postoperative complications were detected.

Conclusions:

The Tecnis Symfony lenses implantation was a safe and effective method for patients who want to be spectacle independent at different distances.

Financial Disclosure:

NONE

Back to previous